Latest Treatment Perspectives for IBD-related Arthritis - a review
DOI:
https://doi.org/10.12775/JEHS.2024.61.004Keywords
Gastroenterology, Rheumatology, Arthritis, Extraintestinal manifestations, IBD, TreatmentAbstract
Introduction: IBD-related arthritis (spondyloarthropathy) is the most common extraintestinal manifestation (EIM) of inflammatory bowel disease (IBD) and is often considered a formidable clinical challenge. Emergence of TNFα-antagonists has revolutionised the clinical approach to management of IBD-related arthritis and remains the mainstay of the therapy. However, its use presents several limitations, underscoring the need for new treatment modalities. Recently, new agents have been approved for the management of IBD, although their influence on IBD-related arthritis has been scarcely investigated.
Aim of the Study: The aim of the study was to collect and analyse current literature regarding the efficacy of new agents used for treating IBD-related arthritis.
Methods and Materials: Extensive research was conducted using the PubMed, ScienceDirect database and Google Scholar, with the primary focus on literature from the past 5 years. Firstly, potential novel treatment options for IBD-related arthritis were obtained. The names of the drugs were juxtaposed with terms related to “IBD-related arthritis” to gather data regarding their efficacy in said condition. Additionally, references from selected articles were included in the analysis.
Results: Emerging treatment options show promising results in achieving remission of IBD-related arthritis. However, our study revealed research gap as the current literature lacks large-scale, prospective studies that assess the efficacy of the aforementioned agents in achieving a resolution of IBD-related arthritis. Therefore, the results of our study encourage further research, with special emphasis on large-scale randomised controlled trials.
References
Winter MW, Weinstock JV. Inflammatory Bowel Disease. In: The Autoimmune Diseases. Elsevier; 2020:871-894. doi:10.1016/B978-0-12-812102-3.00046-4
Larsen S, Bendtzen K, Nielsen OH. Extraintestinal manifestations of inflammatory bowel disease: Epidemiology, diagnosis, and management. Ann Med. 2010;42(2):97-114. doi:10.3109/07853890903559724
Palm Ø, Bernklev T, Moum B, Gran JT. Non-inflammatory joint pain in patients with inflammatory bowel disease is prevalent and has a significant impact on health related quality of life. J Rheumatol. 2005;32(9):1755-1759.
Ott C, Schölmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol. 2013;10(10):585-595. doi:10.1038/nrgastro.2013.117
Hedin CRH, Vavricka SR, Stagg AJ, et al. The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy. J Crohns Colitis. 2019;13(5):541-554. doi:10.1093/ecco-jcc/jjy191
Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19-34. doi:10.1136/ard-2022-223296
Harbord M, Annese V, Vavricka SR, et al. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis. 2016;10(3):239-254. doi:10.1093/ecco-jcc/jjv213
Moninuola OO, Milligan W, Lochhead P, Khalili H. Systematic review with meta‐analysis: association between acetaminophen and nonsteroidal anti‐inflammatory drugs ( NSAID s) and risk of Crohn’s disease and ulcerative colitis exacerbation. Aliment Pharmacol Ther. 2018;47(11):1428-1439. doi:10.1111/apt.14606
Long MD, Kappelman MD, Martin CF, Chen W, Anton K, Sandler RS. Role of Nonsteroidal Anti-Inflammatory Drugs in Exacerbations of Inflammatory Bowel Disease. J Clin Gastroenterol. 2016;50(2):152-156. doi:10.1097/MCG.0000000000000421
Gordon H, Burisch J, Ellul P, et al. ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis. Published online June 23, 2023:jjad108. doi:10.1093/ecco-jcc/jjad108
Iriarte A, Zaera C, Bachiller-Corral J, López-Sanromán A. Enfermedad inflamatoria intestinal como efecto paradójico del tratamiento con anti-TNF-α. Gastroenterol Hepatol. 2017;40(2):117-121. doi:10.1016/j.gastrohep.2016.01.011
Mitoma H, Horiuchi T, Tsukamoto H, Ueda N. Molecular mechanisms of action of anti-TNF-α agents – Comparison among therapeutic TNF-α antagonists. Cytokine. 2018;101:56-63. doi:10.1016/j.cyto.2016.08.014
Atreya R, Neurath MF. IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality. J Crohns Colitis. 2022;16(Supplement_2):ii54-ii63. doi:10.1093/ecco-jcc/jjac007
Peyrin-Biroulet L, Van Assche G, Gómez-Ulloa D, et al. Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2017;15(1):25-36.e27. doi:10.1016/j.cgh.2016.06.025
Vavricka SR, Gubler M, Gantenbein C, et al. Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study: Inflamm Bowel Dis. 2017;23(7):1174-1181. doi:10.1097/MIB.0000000000001109
Roda G, Jharap B, Neeraj N, Colombel JF. Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management. Clin Transl Gastroenterol. 2016;7(1):e135. doi:10.1038/ctg.2015.63
Nielsen OH, Boye TL, Gubatan J, Chakravarti D, Jaquith JB, LaCasse EC. Selective JAK1 inhibitors for the treatment of inflammatory bowel disease. Pharmacol Ther. 2023;245:108402. doi:10.1016/j.pharmthera.2023.108402
Gratacós Masmitjà J, González Fernández CM, Gómez Castro S, Rebollo Laserna FJ. Efficacy of Tofacitinib in the Treatment of Psoriatic Arthritis: A Systematic Review. Adv Ther. 2021;38(2):868-884. doi:10.1007/s12325-020-01585-7
Harrington R, Harkins P, Conway R. Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib. J Clin Med. 2023;12(20):6690. doi:10.3390/jcm12206690
Herrera-deGuise C, Serra-Ruiz X, Lastiri E, Borruel N. JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases. Front Med. 2023;10:1089099. doi:10.3389/fmed.2023.1089099
Wang W, Cleveland NK, Ollech J, Rubin DT. Use of Tofacitinib for the Treatment of Arthritis Associated With Ulcerative Colitis. ACG Case Rep J. 2019;6(9):e00226. doi:10.14309/crj.0000000000000226
Le Berre C, Loeuille D, Peyrin-Biroulet L. Combination Therapy With Vedolizumab and Tofacitinib in a Patient With Ulcerative Colitis and Spondyloarthropathy. Clin Gastroenterol Hepatol. 2019;17(4):794-796. doi:10.1016/j.cgh.2018.08.017
Momen Majumder MS, Haq SA, Rasker JJ. Tofacitinib for the treatment of inflammatory bowel disease-associated arthritis: two case reports. J Med Case Reports. 2023;17(1):71. doi:10.1186/s13256-023-03796-2
Lomborg N, Jensen MD. Effect of tofacitinib in a patient with inflammatory bowel disease–related arthritis. Mod Rheumatol Case Rep. 2022;6(2):171-172. doi:10.1093/mrcr/rxac021
Rubin DT, Reinisch W, Greuter T, et al. Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis. Ther Adv Gastroenterol. 2021;14:175628482110057. doi:10.1177/17562848211005708
Fonseca D, Nogueira M, Torres T. Upadacitinib for the treatment of psoriatic arthritis. Drugs Context. 2023;12:1-13. doi:10.7573/dic.2022-11-6
Sanmartí R, Corominas H. Upadacitinib for Patients with Rheumatoid Arthritis: A Comprehensive Review. J Clin Med. 2023;12(5):1734. doi:10.3390/jcm12051734
Baraliakos X, Van Der Heijde D, Sieper J, et al. Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study. Arthritis Res Ther. 2023;25(1):172. doi:10.1186/s13075-023-03128-1
Loftus EV, Panés J, Lacerda AP, et al. Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med. 2023;388(21):1966-1980. doi:10.1056/NEJMoa2212728
Colombel JF, Cao Q, Ghosh S, et al. Tu1455: EFFECT OF UPADACITINIB (UPA) TREATMENT ON EXTRAINTESTINAL MANIFESTATIONS (EIMS) IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS (UC): RESULTS FROM THE UPA PHASE 3 PROGRAMME. Gastroenterology. 2022;162(7):S-968. doi:10.1016/S0016-5085(22)62293-5
Peyrin-Biroulet L, Danese S, Louis E, et al. DOP50 Effect of upadacitinib on extra-intestinal manifestations in patients with moderate to severe Crohn’s disease: data from the CELEST study. J Crohns Colitis. 2019;13(Supplement_1):S057-S057. doi:10.1093/ecco-jcc/jjy222.084
Smolen JS, Xie L, Jia B, et al. Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study. Rheumatology. 2021;60(5):2256-2266. doi:10.1093/rheumatology/keaa576
Feagan BG, Danese S, Loftus EV, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. The Lancet. 2021;397(10292):2372-2384. doi:10.1016/S0140-6736(21)00666-8
Pugliese D, Daperno M, Fiorino G, et al. Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study. Dig Liver Dis. 2019;51(7):972-977. doi:10.1016/j.dld.2019.03.007
Freuer D, Linseisen J, Meisinger C. Association Between Inflammatory Bowel Disease and Both Psoriasis and Psoriatic Arthritis: A Bidirectional 2-Sample Mendelian Randomization Study. JAMA Dermatol. 2022;158(11):1262-1268. doi:10.1001/jamadermatol.2022.3682
Biemans VBC, Van Der Meulen - De Jong AE, Van Der Woude CJ, et al. Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study. J Crohns Colitis. 2020;14(1):33-45. doi:10.1093/ecco-jcc/jjz119
Liefferinckx C, Verstockt B, Gils A, et al. Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn’s Disease Who Failed Biologic Therapies: A National Cohort Study. J Crohns Colitis. 2019;13(11):1401-1409. doi:10.1093/ecco-jcc/jjz080
Narula N, Aruljothy A, Wong ECL, et al. The impact of ustekinumab on extraintestinal manifestations of Crohn’s disease: A post hoc analysis of the UNITI studies. United Eur Gastroenterol J. 2021;9(5):581-589. doi:10.1002/ueg2.12094
Matsumoto S, Matsumoto K, Takaya H, Otake H, Mashima H. Efficacy of Ustekinumab Against Spondyloarthritis Associated with Crohn’s Disease: A Case Report and Review of the Literature. Open Access Rheumatol Res Rev. 2020;Volume 12:133-137. doi:10.2147/OARRR.S263259
Matsumoto S, Mashima H. Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease. Biol Targets Ther. 2018;Volume 12:69-73. doi:10.2147/BTT.S169326
Brüner M, Dige A, Loft AG, et al. Spondylitis-psoriasis-enthesitis-enterocolitis-dactylitis-uveitis-peripheral synovitis (SPEED-UP) treatment. Autoimmun Rev. 2021;20(2):102731. doi:10.1016/j.autrev.2020.102731
Fleisher M, Marsal J, Lee SD, et al. Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease. Dig Dis Sci. 2018;63(4):825-833. doi:10.1007/s10620-018-4971-1
Feagan BG, Sandborn WJ, Colombel JF, et al. Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials. J Crohns Colitis. 2019;13(1):50-57. doi:10.1093/ecco-jcc/jjy125
Tadbiri S, Peyrin‐Biroulet L, Serrero M, et al. Impact of vedolizumab therapy on extra‐intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV ‐ IBD cohort. Aliment Pharmacol Ther. 2018;47(4):485-493. doi:10.1111/apt.14419
Dubash S, Marianayagam T, Tinazzi I, et al. Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease. Rheumatology. 2019;58(6):963-968. doi:10.1093/rheumatology/key267
Varkas G, Thevissen K, De Brabanter G, et al. An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series. Ann Rheum Dis. 2017;76(5):878-881. doi:10.1136/annrheumdis-2016-210233
Ramos GP, Dimopoulos C, McDonald NM, et al. The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study. Inflamm Bowel Dis. 2021;27(8):1270-1276. doi:10.1093/ibd/izaa293
De Galan C, Truyens M, Peeters H, et al. The Impact of Vedolizumab and Ustekinumab on Articular Extra-Intestinal Manifestations in Inflammatory Bowel Disease Patients: A Real-Life Multicentre Cohort Study. J Crohns Colitis. 2022;16(11):1676-1686. doi:10.1093/ecco-jcc/jjac058
Macaluso FS, Orlando R, Fries W, et al. The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases. Dig Liver Dis. 2018;50(7):675-681. doi:10.1016/j.dld.2018.02.013
Kopylov U, Burisch J, Ben-Horin S, et al. Impact of Vedolizumab on Extraintestinal Manifestations in Inflammatory Bowel Disease: Results From a Descriptive, Retrospective, Real-world Study. Inflamm Bowel Dis. 2023;29(11):1713-1722. doi:10.1093/ibd/izad075
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Michał Sęk, Olgerd Duchnevič, Iwona Galasińska, Katarzyna Hajduk-Maślak, Aleksandra Szypuła, Beniamin Michalik, Adrianna Skóra
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 462
Number of citations: 0
